KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Equivalents (2016 - 2025)

Pacific Biosciences Of California has reported Cash & Equivalents over the past 16 years, most recently at $63.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $63.7 million for Q4 2025, up 15.06% from a year ago — trailing twelve months through Dec 2025 was $63.7 million (up 15.06% YoY), and the annual figure for FY2025 was $63.7 million, up 15.06%.
  • Cash & Equivalents for Q4 2025 was $63.7 million at Pacific Biosciences Of California, up from $56.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PACB hit a ceiling of $932.4 million in Q1 2021 and a floor of $54.8 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $209.3 million (2023), compared with a mean of $257.5 million.
  • Biggest five-year swings in Cash & Equivalents: surged 1254.01% in 2021 and later tumbled 79.78% in 2024.
  • Pacific Biosciences Of California's Cash & Equivalents stood at $460.7 million in 2021, then fell by 29.44% to $325.1 million in 2022, then crashed by 44.66% to $179.9 million in 2023, then plummeted by 69.22% to $55.4 million in 2024, then increased by 15.06% to $63.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $63.7 million (Q4 2025), $56.5 million (Q3 2025), and $54.8 million (Q2 2025) per Business Quant data.